Shots:

• Henlius to receive upfront- regulatory- and commercial milestone payments of ~$43M- eligible to receive $30M for every $1B above the first $600M of the cumulative net sales along with 10% royalties on net sales of the therapy
• Henlius will be responsible for the pre/ clinical development of HLX04- whereas Essex is responsible for regulatory filings and commercialization of HLX04 globally and will be responsible for 80% of all costs and expenses concerning to the development of HLX04. Additionally- Essex has a right to grant a sublicense to third parties- for which Henlius will receive 20% of the related sublicensing revenue
• Henlius is developing HLX04 for ophthalmic diseases- wAMD & DR. Henlius and Essex plan to conduct global clinical trials of HLX04 in China- Australia- EU & the US- & will apply MAA in different countries across the globe

 ­ Ref: Henlius | Image: BioSpectrum Asia